|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/18 | |
| A61P 7/06 | |||
| A61K 38/20 | |||
| A61K 47/48 | |||
| A61K 39/395 |
| (11) | Number of the document | 1330260 |
| (13) | Kind of document | T |
| (96) | European patent application number | 01992582.5 |
| Date of filing the European patent application | 2001-10-30 | |
| (97) | Date of publication of the European application | 2003-07-30 |
| (45) | Date of publication and mention of the grant of the patent | 2014-05-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2001/046205 |
| Date | 2001-10-30 |
| (87) | Number | WO 2002/036152 |
| Date | 2002-05-10 |
| (30) | Number | Date | Country code |
| 244792 P | 2000-10-31 | US | |
| 969739 | 2001-10-02 | US |
| (72) |
KAY, Jonathan, US
MCCABE, Dorothy, US
NEWMARK, Richard, US
COCCIA, Marco, A., US
|
| (73) |
AMGEN INC.,
One Amgen Center Drive, Thousand Oaks, CA 91320-1799,
US
|
| (54) | USE OF IL-1 INHIBITORS AND TNF ANTAGONISTS, PARTIALLY IN COMBINATION WITH RECOMBINANT ERYTHROPOIETINS, FOR THE TREATMENT OF ANEMIA |
| USE OF IL-1 INHIBITORS AND TNF ANTAGONISTS, PARTIALLY IN COMBINATION WITH RECOMBINANT ERYTHROPOIETINS, FOR THE TREATMENT OF ANEMIA |